REFERENCES
Coeman D, Verbeken K, Nackaerts M, Demedts MG, Vansteenkiste JF: A fatal case of cholestatic liver failure probably related to gemcitabine. Ann Oncol 11:1503–1504, 2000
Samlowski W, Gundacker H, Kuebler P, Giguere JK, Mills GM, Schuller DE, Ensley JF: Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A southwest oncology group phase II study. Investi New Drugs 19:311–315, 2001
Venook A, Egorin M, Rosner G: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565. J Clini Oncol 18(14):2780–2787, 2000
Sessa C, Aamadal S, Wolfe I: Gemcitabine in patients with advanced malignant melanoma or gastric cancer. Phase II studies of the EORTC early clinical trials group. Ann Oncol 5:471–472, 1994
Ostapowicz G, Lee WM: Acute hepatic failure: a western perspective. J Gastroenterol Hepatol 15:480, 2000
Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, Stribling R, Crippin JS, Flamm S, Somberg KA, Rosen H, MsCahland TM, Hay JE, Lee WM: Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl and Surg 5:29, 1999
Feldman M, Scharschmidt BF, Sleisenger MH (eds.). Sleisenger's and Fordtran's Gastrointestinal and Liver Disease, 7th ed., WB Saunders, Philadelphia.
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116, 1984
Rosenberg WMC, Ryley NG, Trowell JM, McGee JO, Chapman RW: Dextro-propoxyphene-induced hepatotoxicity: A report of nine cases. J Hepatol 19:470, 1993
Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC: Trends in alternative medicine use in the United States, 1990–1997. JAMA 280:1569, 1998
Winslow LC, Kroll DJ: Herbs as medicines. Arch Intern Med 158:2192, 1998
Angell M, Kassirer JP: Alternative medicine-the risks of untested and unregulated remedies. N Engl J Med 339:839, 1998
Bensoussan A: Complementary medicine-where lies its appeal? Med J Aust 170:247, 1999
Chan TY, Chan JC, Tomlinson B, Critchley JA: Chinese herbal medicines revisited: A Hong Kong perspective, Lancet 342:1532, 1993
Dobbie M, Hofer S, Oberholzer M, et al: Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol 9:681, 1998
Oettle H, Pelzer U, Hochmuth, K: Phase I trial of gemcitabine (Gemzar), 24-hour infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs 10:699–704, 1999
Hruban R, Sternberg S, Meyers P, Fleisher M, Menendez-Botet C, Boitnott JK: Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 9(3):263–268, 1991
Kurita Y, Yokoyama A, Matsui K, Hara N, Nakai Y, Ohhashi Y, Niitani H: Phase I study of gemcitabine hydrochloride combination therapy with cisplatin in the patients with non-small cell lung cancer. Cancer Chemother 26(7):898–907, 1999
Rights and permissions
About this article
Cite this article
Robinson, K., Lambiase, L., Li, J. et al. CASE REPORT: Fatal Cholestatic Liver Failure Associated with Gemcitabine Therapy. Dig Dis Sci 48, 1804–1808 (2003). https://doi.org/10.1023/A:1025415616592
Issue Date:
DOI: https://doi.org/10.1023/A:1025415616592